China is world No 2 economy, therefore there are many China business related stocks in the world (Singapore, China, Hong Kong, Taiwan, US). The quality of China related stocks could vary significantly, including 111 S-Chip stocks in Singapore with 20% weak stocks are suspended and also some strong China stocks could double the share price in a short period. In this article, you will learn from Dr Tee on 4 China related Giant Stocks which are efficient in making money with strong business growth in Greater China market (China, Hong Kong, Taiwan). Bonus for readers who could read every words of the entire article, learning unique strategy for each giant stock. 1) Singapore All-Rounded Giant Stock (S-Chip / A-Share) – Tianjin Zhongxin Pharmaceutical Group (SGX: T14 / China

Between life and money, which is more important? In this article, you will learn from Dr Tee on 11 Singapore Healthcare Giant Stocks which are efficient in making money with life as an economic moat, while some surge in prices during COVID-19 stock crisis. 1) COVID-19 “Crisis as Opportunity” Stocks Medtecs International Corporation (SGX: 546) UG Healthcare Corporation (SGX: 41A) Top Glove Corporation (SGX: BVA) Riverstone Holdings (SGX: AP4) 2) Medical Services Stocks Q&M Dental Group (SGX: QC7) Raffles Medical Group (SGX: BSL) 3) Healthcare Products Stocks Tianjin Zhong Xin Pharmaceutical Group (SGX: T14) Haw Par Corporation (SGX: H02) 4) Healthcare REITs First Reit (SGX: AW9U) ParkwayLife Reit (SGX: C2PU) IHH Healthcare (SGX: Q0F)

Healthcare stocks (eg. hospital business, pharmaceutical companies, vaccine development, etc.) are having competitive advantages, therefore those with growing businesses are usually growth giant stocks. Between life and money, which is more important? The choice is clear (金钱诚可贵、生命价更高) to put life at a higher priority, therefore healthcare has been a high growth sector in most countries. Q&M Dental (SGX: QC7) is a young healthcare giant stock with focus in dental services. The company started business in year 1996, having main businesses in Singapore (79 branches), Malaysia and China.  For China, due to stronger competition and higher cost, subsidiary stock, Aoxin Q&M (SGX: 1D4) with poorer business there, is not a giant stock, not performing as go